

09-27-2002

912310Z



Form PTO-1595 (Rev. 03/01) RECC  
OMB No. 0651-0027 (exp. 5/31/2002)

102234581  
PATENTS ONLY

U.S. DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office  
Washington, D.C. 20231  
Box ASSIGNMENT

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof

1. Name of conveying party(ies):

Licentia Ltd.

Additional name(s) of conveying party(ies) attached?  Yes  No

2. Name and address of receiving party(ies)

Name: LUDWIG INSTITUTE FOR CANCER RESEARCH

A swiss not-for-profit corporation

Street Address:

605 Third Avenue

City: New York

State: NY Zip: 10158

Additional name(s) & address(es) attached:  Yes  No

3. Nature of Conveyance:

Assignment 50%  Merger  
 Security Agreement  Change of Name  
 Other

Execution Date: June 25, 2002

4. Application number(s) or patent number(s):

A. Patent Application No.(s): 09/169079

B. Patent No.(s):

Additional numbers attached?  Yes  No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: David A. Gass  
MARSHALL, GERSTEIN & BORUN

Client Matter No.: 28967/34891

Street Address:

6300 Sears Tower  
233 S. Wacker Drive

City: Chicago State: IL Zip: 60606-6357

6. Total number of applications and patents involved:

7. Total fee (37 CFR 3.41) \$ 40.00  
 Enclosed  
 Authorized to be charged to deposit account  
 Authorized to be charged to credit card (Form 2038 enclosed)

8. Deposit account number:

13-2855  
(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

David A. Gass - 38,153  
Name of Person Signing

*David A. Gass*  
Signature

Sep 18, 2002  
Date

Total number of pages including cover sheet, attachments, and documents: 3

09/25/2002 DBYRNE 00000188 09169079

01 FC:581

40.00 OP

## ASSIGNMENT

WHEREAS Licentia Ltd., Erottajankatu 19 B, 6<sup>th</sup> floor, FIN-00130 Helsinki, Finland, its successors and assigns, is the assignee of the entire right, title and interest in the invention or improvements of Kari Alitalo, Arja Kaipainen, Reija Valtola, and Lotta Jussila relating to Flt4 (VEGFR-3) as a Target for Tumor Imaging and Anti-tumor Therapy disclosed in certain applications for Letters Patent of the United States, and in said applications and any and all other applications, both United States and non-U.S., which Kari Alitalo, Arja Kaipainen, Reija Valtola, and Lotta Jussila may file, either solely or jointly with others, on said invention or improvements, and in any and all Letters Patent of the United States and non-U.S. countries, which may be obtained on any of said applications, and in any reissue or extension thereof; and

WHEREAS, for ten dollars and other good and valuable consideration enumerated in a written agreement the sufficiency of which is hereby acknowledged, Licentia Ltd. has agreed to share ownership of the aforementioned inventions, improvements, applications, patents, reissues, extensions, and the like on a 50%/50% equal basis with Ludwig Institute for Cancer Research, a Swiss not-for-profit corporation having offices at 605 Third Avenue, New York, New York, 10158, United States of America;

NOW, THEREFORE, for ten dollars and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned, Licentia Ltd., Erottajankatu 19 B, 6<sup>th</sup> floor, FIN-00130 Helsinki, Finland hereby assigns to Ludwig Institute for Cancer Research, a Swiss not-for-profit corporation having offices at 605 Third Avenue, New York, New York, 10158, United States of America, (hereinafter "assignee"), its successors and assigns, fifty percent (50%) right, title and interest in the invention or improvements disclosed in the below-identified applications for Letters Patent of the United States (U.S.), and in said application and any and all other applications on said invention or improvements, both United States and non-U.S., including:

<u>Application No.</u>	<u>Country</u>	<u>Title</u>
09/169,079	US	<b>FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy</b>
13121/00	AU	<b>FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy</b>
2345276	CA	<b>FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy</b>
99814285.9	CN	<b>FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy</b>
99956525.2	EPO	<b>FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy</b>
575533	JP	<b>FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy</b>

511408

NZ

**FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy**

20011759

NO

**FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy**

PCT/US99/23525

PCT

**FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy;**

and in any and all Letters Patent of the United States and non-U.S. countries, which may be obtained on any of said applications, and in any reissue or extension thereof.

The undersigned warrants himself to be the owner of the interest herein assigned and to have the right to make this assignment and further warrants that there are no outstanding prior assignments, licenses, or other rights in the interest herein assigned.




Timo Törmälä  
President


Licentia Ltd.  
Erottajankatu 19 B, 6<sup>th</sup> floor  
FIN-00130 Helsinki, Finland

WITNESSES:

On this 25 day of June, 2002 before me, appeared Timo Törmälä, to me personally known to be the same person whose name is subscribed to the foregoing instrument, and acknowledged that he executed said instrument as his free and voluntary act and for the uses and purposes therein expressed.

Signature: 

Name: PAULI SEPPANEN  
(Printed)

Signature: 

Name: Jukka Hiltunen  
(Printed)